Estimating cancer risk from 99mTc pyrophosphate imaging for transthyretin cardiac amyloidosis

Estimating cancer risk from 99mTc pyrophosphate imaging for transthyretin cardiac amyloidosis ORIGINAL ARTICLE 99m Estimating cancer risk from Tc pyrophosphate imaging for transthyretin cardiac amyloidosis a,b c Andrew J. Einstein, MD, PhD, FASNC, Igor Shuryak, MD, PhD, Adam Castan˜o, a b a MD, MS, Akiva Mintz, MD, PhD, Mathew S. Maurer, MD, and Sabahat Bokhari, MD, FASNC Division of Cardiology, Department of Medicine, Columbia University Irving Medical Center and New York-Presbyterian Hospital, New York Department of Radiology, Columbia University Irving Medical Center and New York- Presbyterian Hospital, New York Center for Radiological Research, Columbia University Irving Medical Center, New York Received Apr 2, 2018; accepted May 10, 2018 doi:10.1007/s12350-018-1307-7 Background. Increasing recognition that transthyretin cardiac amyloidosis (ATTR-CA) is much more common than previously appreciated and the emergence of novel disease-modifying therapeutic agents have led to a paradigm shift in which ATTR-CA screening is considered in high-risk populations, such as patients with heart failure with preserved ejection fraction 99m 99m (HFpEF) or aortic stenosis. Radiation risk from Tc-pyrophosphate ( Tc-PYP) scintigra- phy, a test with very high sensitivity and specificity for ATTR-CA, has not been previously determined. 99m Methods and Results. Radiation doses to individual organs from Tc-PYP were estimated using models developed by the Medical Internal Radiation Dose Committee and http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Journal of Nuclear Cardiology Springer Journals

Estimating cancer risk from 99mTc pyrophosphate imaging for transthyretin cardiac amyloidosis

Loading next page...
 
/lp/springer_journal/estimating-cancer-risk-from-99mtc-pyrophosphate-imaging-for-lEQG00nveM
Publisher
Springer US
Copyright
Copyright © 2018 by American Society of Nuclear Cardiology
Subject
Medicine & Public Health; Cardiology; Nuclear Medicine; Imaging / Radiology
ISSN
1071-3581
eISSN
1532-6551
D.O.I.
10.1007/s12350-018-1307-7
Publisher site
See Article on Publisher Site

Abstract

ORIGINAL ARTICLE 99m Estimating cancer risk from Tc pyrophosphate imaging for transthyretin cardiac amyloidosis a,b c Andrew J. Einstein, MD, PhD, FASNC, Igor Shuryak, MD, PhD, Adam Castan˜o, a b a MD, MS, Akiva Mintz, MD, PhD, Mathew S. Maurer, MD, and Sabahat Bokhari, MD, FASNC Division of Cardiology, Department of Medicine, Columbia University Irving Medical Center and New York-Presbyterian Hospital, New York Department of Radiology, Columbia University Irving Medical Center and New York- Presbyterian Hospital, New York Center for Radiological Research, Columbia University Irving Medical Center, New York Received Apr 2, 2018; accepted May 10, 2018 doi:10.1007/s12350-018-1307-7 Background. Increasing recognition that transthyretin cardiac amyloidosis (ATTR-CA) is much more common than previously appreciated and the emergence of novel disease-modifying therapeutic agents have led to a paradigm shift in which ATTR-CA screening is considered in high-risk populations, such as patients with heart failure with preserved ejection fraction 99m 99m (HFpEF) or aortic stenosis. Radiation risk from Tc-pyrophosphate ( Tc-PYP) scintigra- phy, a test with very high sensitivity and specificity for ATTR-CA, has not been previously determined. 99m Methods and Results. Radiation doses to individual organs from Tc-PYP were estimated using models developed by the Medical Internal Radiation Dose Committee and

Journal

Journal of Nuclear CardiologySpringer Journals

Published: May 30, 2018

References

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Search

Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly

Organize

Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.

Access

Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

DeepDyve

Freelancer

DeepDyve

Pro

Price

FREE

$49/month
$360/year

Save searches from
Google Scholar,
PubMed

Create lists to
organize your research

Export lists, citations

Read DeepDyve articles

Abstract access only

Unlimited access to over
18 million full-text articles

Print

20 pages / month

PDF Discount

20% off